BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?

No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!



BAILII [Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback]

United Kingdom Statutory Instruments
You are here: BAILII >> Databases >> United Kingdom Statutory Instruments >> The Medicines for Human Use and Medical Devices (Fees and Miscellaneous Amendments) Regulations 2001 No. 795
URL: http://www.bailii.org/uk/legis/num_reg/2001/20010795.html

[New search] [Help]

STATUTORY INSTRUMENTS

2001 No. 795

MEDICINES

FEES AND CHARGES

The Medicines for Human Use and Medical Devices (Fees and Miscellaneous Amendments) Regulations 2001

  Made 8th March 2001 
  Laid before Parliament 9th March 2001 
  Coming into force 1st April 2001 

The Secretary of State, being a Minister designated for the purposes of section 2(2) of the European Communities Act 1972[1] in relation to medicinal products[2], in exercise of the powers conferred upon him by the said section 2(2), the Secretary of State, with the consent of the Treasury, in exercise of the powers conferred upon him by section 56(1) and (2) of the Finance Act 1973[3], the Secretary of State concerned with health in England, the Minister of Agriculture, Fisheries and Food, the Minister of Health, Social Services and Public Safety and the Minister of Agriculture and Rural Development, acting jointly and with the consent of the Treasury, in exercise of powers conferred upon them by section 1(1) and (2) of the Medicines Act 1971[4], or, as the case may be, powers conferred by those provisions and now vested in them[5], and in each case in exercise of all other powers respectively enabling them in that behalf, after consultation in accordance with section 129(6) of the Medicines Act 1968[6], as extended by section 1(3)(b) of the Medicines Act 1971, with such organisations as appear to them to be representative of interests likely to be substantially affected, hereby make the following Regulations: - 

Citation, commencement and interpretation
     1.  - (1) These Regulations may be cited as the Medicines for Human Use and Medical Devices (Fees and Miscellaneous Amendments) Regulations 2001 and shall come into force on 1st April 2001.

    (2) In these Regulations - 

Amendment of the Marketing Authorisations Regulations
     2.  - (1) In regulation 1(2) of the Marketing Authorisations Regulations (interpretation) - 

    (2) In regulation 4(1) of the Marketing Authorisations Regulations (applications for the grant, renewal or variation of a United Kingdom marketing authorisation), for the words "any provision of Community law affecting" there shall be substituted the words "the rules of Community law relating to".

    (3) In regulation 5 of the Marketing Authorisations Regulations (consideration, and grant or refusal, of an application for, or for renewal or variation of, a United Kingdom marketing authorisation) - 

Amendment of the Homoeopathic Products Regulations
     3.  - (1) In regulation 1(2) of the Homoeopathic Products Regulations[13] (interpretation), in the definition of "standard variation" - 

    (2) In regulation 14[14] of the Homoeopathic Products Regulations (fees for variations of certificates) - 

    (3) In regulation 15(1)[15] of the Homoeopathic Products Regulations (fees payable by holders of certificates), for "£11" there shall be substituted "£12".

    (4) In the Table in Schedule 2 to the Homoeopathic Products Regulations[16] (fees for applications for the grant of certificates of registration) - 

Amendment of regulation 3 of the Devices Regulations
     4. In regulation 3 of the Devices Regulations[17] (fees) - 

Amendment of the General Fees Regulations
     5.  - (1) In regulation 2(1) of the General Fees Regulations[18] (interpretation) - 

    (2) Regulations 4A, 4B, and 4C of the General Fees Regulations[23] shall be renumbered regulations 6A, 6B and 6C respectively.

    (3) In regulation 6(2) of the General Fees Regulations (applications for certificates by exporters of medicinal products) - 

    (4) In regulation 16(1) of the General Fees Regulations[24] (time for payment in connection with applications or inspections) for "4C" there shall be substituted "6C".

    (5) In paragraph 1 of Part I of Schedule 1 to the General Fees Regulations (interpretation), in the definition of "standard application", for the words "marketing authorisation (parallel import)", there shall be substituted the words "parallel import licence".

    (6) In entry 5 in column 1 in the table in paragraph 1 of Part II of Schedule 1 to the General Fees Regulations (capital fees for applications for authorisations, licences and certificates), for the words "marketing authorisation (parallel import)" there shall be substituted the words "parallel import licence".

    (7) In paragraph 2 of Part IIA of Schedule 1 to the General Fees Regulations[25] (outgoing mutual recognition applications), for "4B" there shall be substituted "6B".

    (8) In paragraph 1 of Part III of Schedule 1 to the General Fees Regulations (capital fees for variations of authorisations, licences and certificates), in the definitions of "Type I Application" and "Type II Application", for the words "marketing authorisation (parallel import)", at each place where they occur, there shall be substituted the words "parallel import licence".

    (9) In paragraph 6 of Part III of Schedule 1 to the General Fees Regulations - 

    (10) In paragraph 1 of Part IV of Schedule 3 to the General Fees Regulations (types of marketing authorisation for which only one periodic fee is payable), for the words "Marketing authorisations (parallel import)" there shall be substituted the words "Parallel import licences"

    (11) In paragraph 4A of Schedule 4 to the General Fees Regulations [26] (time for payment of capital fees - applications by small companies), for "4B" there shall be substituted "6B".

    (12) After paragraph 2 of Schedule 5 to the General Fees Regulations (waiver, reduction or refund of capital fees) there shall be inserted the following paragraph - 

    (13) In paragraph 6 of Schedule 5 to the General Fees Regulations - 

    (14) In each provision of the General Fees Regulations specified in the entries in column (1) of the Schedule to these Regulations (the content of which is described in column (2) of that Schedule), for the amount specified opposite that provision in column (3) of that Schedule there shall be substituted the amount specified opposite that provision in column (4) of that Schedule.



Signed by authority of the Secretary of State for Health


Hunt
Parliamentary Under Secretary of State, Department of Health

5th March 2001


Hayman
Minister of State, Ministry of Agriculture, Fisheries and Food

6th March 2001


Bairbre de Brún
Minister of Health, Social Services and Public Safety

7th March 2001


Bríd Rodgers
Minister of Agriculture and Rural Development

7th March 2001



We consent,


Greg Pope

Jim Dowd
Two of the Lords Commissioners of Her Majesty's Treasury

8th March 2001



SCHEDULE
Regulation 5(14)

Column (1) Column (2) Column (3) Column (4)
Provision in the General Regulations Subject matter Old amount New amount
Regulation 6 Applications for certificates by exporters of medicinal products          
Paragraph (1)(a)      £96 £100
Paragraph (1)(b)      £34 £44
Paragraph (1)(c)(i)      £34 £44
Paragraph (1)(c)(ii)      £17 £22
Regulation 10 Renewals of clinical trial certificates £1,795 £1,885
Regulation 11(1) Renewals of certain manufacturer's licences £102 £107
Part II of Schedule 1 Capital fees for applications for authorisations, licences and certificates          
In column 2 of the Table in paragraph 1(1)               
Entry 1(a)      £21,545 £22,622
Entry 1(b)      £46,085 £48,389
Entry 1(c)      £65,835 £69,127
Entry 2(a)      £12,568 £13,196
Entry 2(b)      £17,955 £18,853
Entry 3(a)      £4,605 £4,835
Entry 3(b)      £6,584 £6,913
Entry 4      £1,795 £1,885
Entry 5      £1,196 £1,256
Entry 6      £296 £310
Paragraph 5(1)(a)      £114 £120
Paragraph 5(1)(b)      £216 £227
Paragraph 5(1)(c)      £1,972 £2,070
Paragraph 6(1)      £775 £814
Paragraph 6(2)      £570 £598
Paragraph 6(4)      £250 £262
Paragraph 7      £13,885 £14,579
Part III of Schedule 1 Capital fees for applications for variations of authorisations, licences and certificates          
Paragraph 2(a)      £176 £184
Paragraph 2(b)      £404 £424
Paragraph 2(c)      £5,984 £6,282
Paragraph 3(a)      £274 £288
Paragraph 3(b)      £490 £514
Paragraph 3(c)      £9,336 £9,802
Paragraph 6(a)      £114 £120
Paragraph 6(b)      £239 £251
Paragraph 7(a)      £108 £113
Paragraph 7(b)      £216 £227
Paragraph 8      £108 £113
Paragraph 9      £250 £262
Paragraph 10      £108 £113
Paragraph 11      £176 £185
Paragraph 12      £90 £95
Schedule 2 Fees for inspections          
Paragraph 2(a)(i)      £1,870 £1,964
Paragraph 2(a)(ii)      £3,470 £3,643
Paragraph 2(a)(iii)      £4,190 £4,400
Paragraph 2(a)(iv)      £7,182 £7,541
Paragraph 2(b)(i)      £2,034 £2,136
Paragraph 2(b)(ii)      £4,190 £4,400
Paragraph 2(b)(iii)      £6,582 £6,911
Paragraph 2(b)(iv)      £11,970 £12,568
Paragraph 2(c)(i)      £718 £754
Paragraph 2(c)(ii)      £2,010 £2,110
Paragraph 2(c)(iii)      £3,003 £3,153
Paragraph 2(c)(iv)      £5,625 £5,906
Paragraph 2(d)      £136 £143
Paragraph 5(1)      £376 £395
Paragraph 5(1)      £826 £867
Part III of Schedule 3 Periodic fees for marketing authorisations and licences          
In column 2 of the Table in paragraph 1               
Entry 2(a)      £4,788 £5,027
Entry 2(b)(i)      £1,197 £1,257
Entry 2(b)(ii)      £598 £628
Entry 2(b)(iii)      £194 £204
Entry 2(c)(i)      £524 £550
Entry 2(c)(ii)      £262 £275
Entry 2(c)(iii)      £97 £102
Entry 2(d)(i)      £216 £227
Entry 2(d)(ii)      £108 £113
Entry 2(d)(iii)      £48 £50
Entry 2(e)      £59 £62
Paragraph 2(a)      £268 £280
Paragraph 2(b)      £131 £138
Paragraph 2(c)      £55 £58
Paragraph 3(a)      £4,788 £5,027
Paragraph 3(b)      £3,232 £3,394
Paragraph 7      £239 £251
Paragraph 8(1)      £148 £155
Paragraph 8(2)      £89 £93


EXPLANATORY NOTE

(This note is not part of the Regulations)


These Regulations make further amendments to the Medical Devices (Consultation Requirements) (Fees) Regulations 1995 ("the Devices Regulations"), the Medicines (Products for Human Use - Fees) Regulations 1995 ("the General Fees Regulations"), the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994 ("the Homoeopathic Products Regulations") and the Medicines for Human Use (Marketing Authorisations etc.) Regulations 1994 ("the Marketing Authorisations Regulations").

The Marketing Authorisations Regulations implemented in part the following provisions of the European Community: Council Directives 65/65/EEC[27], 75/318/EEC[28], 75/319/EEC[29] and any Regulation adopted by the Commission under Article 15 of that Directive, 89/342/EEC[30], 89/343/EEC[31], 89/381/EEC[32], 92/26/EEC[33], 92/27/EEC[34], 92/73/EEC[35], Regulation (EEC) No. 2309/93[36] and any Regulations adopted by the Commission under Article 15.4 or 22.1 of that Regulation. They provide for the manner of making applications for the grant, renewal or variation of a United Kingdom marketing authorisation and for procedures for consideration, revocation, suspension and related matters. Regulation 2 of these Regulations amends the Marketing Authorisations Regulations by inserting into regulation 1(2) of those Regulations a definition of "EEA State", omitting the definition of "parallel import", inserting a definition of "parallel import licence" and substituting a new definition of "United Kingdom marketing authorisation". Regulations 2(2) and (3) make amendments consequential on those new definitions. These amendments together with the amendments to the Fees Regulations referred to below clarify the status of the parallel import scheme.

The Homoeopathic Products Regulations implemented in part Council Directive 92/73/EEC[37] by introducing a new registration procedure for the marketing of certain homoeopathic medicinal products for human use. These Regulations amend the Homoeopathic Products Regulations in the following way. Regulation 3(1) of these Regulations adds to the definition of "standard variation", regulation 3(2) increases the amounts of the fees payable for variations of certificates of registration, regulation 3(3) increases the fee payable by holders of certificates of registration and regulation 3(4) increases the amounts of the capital fees payable for applications for certificates of registration. These increases average overall 5%.

The Devices Regulations prescribe the fees which are payable where a notified body consults the competent body in accordance with Council Directive 93/42/EEC[38] concerning medical devices. Regulation 4 of these Regulations amends the Devices Regulations by increasing the amounts of certain of the fees specified in regulation 3 of those Regulations by an average overall of 5%.

The General Fees Regulations make provision for the fees payable under the Medicines Act 1971 relating to marketing authorisations, licences and certificates in respect of medicinal products for human use. These Regualtions amend those Regulations as follows: regulation 5(1) of these Regulations amends regulation 2(1) of those Regulations by inserting a definition of "parallel import licence" and amends the definition of "authorised medicinal product" to take account of this; regulation 5(6), (8), (9), (10) and (13) make amendments consequential on this; these amendments together with those made to the Marketing Authorisations Regulations referred to above clarify the status of the parallel import scheme. Regulation 5(2) renumbers regulations 4A-4C of the General Fees Regulations and regulations 5(4), (7) and (11) make amendments consequential upon this. Regulation 5(3) of these Regulations reduces the number of export certificates comprising a "set". Regulation 5(12) allows for the waiver of any fee payable in connection with a variation application for the purpose of demonstrating compliance with the "Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products", published by the European Commission.

There is also a package of changes to the General Fees Regulations relating to the levels of capital fees payable for applications for marketing authorisations, manufacturer's licences, wholesale dealer's licences, clinical trial certificates and export certificates; capital fees payable for variations and renewals of such authorisations, licences and certificates; periodic fees payable in connection with the holding of certain authorisations and licences; and the fees payable in connection with site inspections. Fees have been increased by approximately 5% except in the case of the fee for export certificates, which is increased by 30%.

A Regulatory Impact Assessment in relation to these Regulations has been placed in the libraries of both Houses of Parliament, and copies can be obtained from the Medicines Control Agency, Room 16107, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.

Notes:

[1] 1972 c.68.back

[2] S.I. 1972/1811.back

[3] 1973 c.51.back

[4] 1971 c. 69; as amended by section 21 of the Health and Medicines Act 1988 (c.49). By virtue of section 1(3) of the 1971 Act, expressions used in that section have the same meaning as in the Medicines Act 1968 (c.67), as amended by article 2(2) of, and Schedule 1 to, S.I. 1969/388 and by article 5 of, and the Schedule to, S.I. 1999/3142; see therefore section 1(1) of the 1968 Act, which contains a definition of "the Ministers" which is relevant to the powers being exercised in the making of these Regulations. See also regultion 9(12) of the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 (S.I. 1994/3144), by virtue of which the references in section 1(1) and (2)(b) of the 1971 Act to a licence under Part II of the 1968 Act include reference to a marketing authorisation under the 1994 Regulations.back

[5] In the case of the Secretary of State concerned with health in England, by virtue of articles 2(1) and 5 of, and the Schedule to, S.I. 1999/3142; in the case of the Minister of Agriculture, Fisheries and Food, by virtue of articles 2(2) and 5 of, and the Schedule to, S.I. 1999/3142; in the case of the Minister of Health, Social Services and Public Safety and the Minister of Agriculture and Rural Development, by virtue of section 95(5) of, and paragraph 10 of Schedule 12 to, the Northern Ireland Act 1998 (c.47).back

[6] 1968 c.67.back

[7] S.I. 1995/449; amended by S.I. 1998/574, 1999/566 and 2000/592.back

[8] S.I. 1995/1116; amended by S.I. 1996/683, 1998/574, 1999/566, 2000/592 and 2000/3031.back

[9] S.I. 1994/105; amended by S.I. 1995/541, 1996/482, 1998/574, 1999/566 and 2000/592.back

[10] S.I. 1994/3144; amended by S.I. 1998/3105 and 2000/292.back

[11] OJ No. L1, 3.1.1994, p.3.back

[12] OJ No. L1, 3.1.1994, p.572.back

[13] As amended by S.I. 1998/574.back

[14] As amended by regulation 2(1) of S.I. 2000/592.back

[15] As amended by regulation 2(2) of S.I. 2000/592.back

[16] As amended by regulation 2(3) of S.I. 2000/592.back

[17] As amended by regulation 3 of S.I. 2000/592.back

[18] As amended by S.I. 1996/683, 2000/592 and 2000/3031.back

[19] OJ No. L22 of 9.2.1965, p.369.back

[20] Council Directive 65/65/EEC has been amended by Directive 66/454/EEC (OJ No. L144, 5.8.1966, p.2658), Council Directive 75/319/EEC (OJ No. L147, 9.6.1975, p.13), Council Directive 83/570/EEC (OJ No. L332, 28.11.1983, p.1), Council Directive 87/21/EEC (OJ No. L15, 17.1.1987, p.36), Council Directive 89/341/EEC (OJ No. L142, 25.5.1989, p.11), Council Directive 89/342/EEC (OJ No. L142, 25.5.1989, p.14), Council Directive 92/27/EEC (OJ No. L113, 30.4.1992, p.8), Council Directive 92/73/EEC (OJ No. L297, 13.10.1992, p.8) and Council Directive 93/39/EEC (OJ No. L215, 24.8.1993, p.22).back

[21] OJ No. L147, 9.6.1975, p.1.back

[22] Council Directive 75/318/EEC has been amended by Council Directive 75/319/EEC (OJ No. L147, 9.6.1975, p.13), Council Directive 83/570/EEC (OJ No. L332, 28.11.1983, p.1), Council Directive 87/19/EEC (OJ No. L15, 17.1.1987, p.31), Council Directive 89/341/EEC (OJ No. L142, 25.5.1989, p.11), Commission Directive 91/507/EEC (OJ No. L270, 26.9.1991, p.32), Council Directive 93/39/EEC (OJ No. L214, 24.8.93, p.22), Commission Directive 1999/82/EC (OJ No. L243, 15.9.1999, p.7) and Commission Directive 1999/83/EC (OJ No. L243, 15.9.1999, p.7).back

[23] Inserted by regulation 3 of S.I. 2000/3031.back

[24] As amended by S.I. 2000/3031.back

[25] Inserted by regulation 6 of S.I. 2000/3031.back

[26] Inserted by regulation 6 of S.I. 2000/3031.back

[27] OJ No. L22, 9.2.1965, p.369.back

[28] OJ No. L147, 9.6.1975, p.1.back

[29] OJ No. L147, 9.6.1975, p.13.back

[30] OJ No. L142, 25.5.1989, p.14.back

[31] OJ No. L142, 25.5.1989, p.16.back

[32] OJ No. L181, 28.6.1989, p.44.back

[33] OJ No. L113, 30.4.1992, p.5.back

[34] OJ No. L113, 30.4.1992, p.8.back

[35] OJ No. L297, 13.10.1992, p.8.back

[36] OJ No. L214, 24.8.1993, p.1.back

[37] OJ No. L297, 13.10.1993, p.8.back

[38] OJ No. L169, 12.7.1993, p.1.back


ISBN 0 11 028990 0


 © Crown copyright 2001

Prepared 21 March 2001

BAILII: Copyright Policy | Disclaimers | Privacy Policy | Feedback | Donate to BAILII
URL: http://www.bailii.org/uk/legis/num_reg/2001/20010795.html